Rheumatology
in Perspective

By Olga Goodman, MD
A RheumaView publication

EN

Patient materials

EnglishРусскийEspañolPolski

Your perspective
PatientCaregiver or family memberInterested readerHealthcare professional
Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Rheumatology in Perspective · by Olga Goodman, MD · A RheumaView publication

Treatment & decisions

You Can’t Be a Little Bit Pregnant

Why rheumatic disease is treated early and seriously — and why “monitoring” is not the same as “wait and see”

Open to everyone

I began my medical career as an obstetrician-gynecologist. I came away with a favorite medical truth that no study has managed to overturn: you can’t be a little bit pregnant. A test with a faint second line exists. The condition “slightly pregnant” does not.

Then I became a rheumatologist and discovered that patients regularly try to get around this truth. Just not in gynecology anymore.

“Doctor, let’s treat it just a little.” “Let’s start with something mild.” “Can I take half the dose? I’m not really a pill person.” “Let’s wait until summer. I always feel better in summer.” “Let me lose some weight first, then we’ll start.”

That last one is my favorite. Inflammation doesn’t go on a diet, and it has no plans to slim down with you.

I understand. Truly. But active inflammation, like pregnancy, has no “a little bit” setting. Either it is there and working, or it has been switched off. Everything in between is not a compromise. It is inflammation carrying on at its own comfortable pace. No weekends, no sick days, no union.

Inflammation doesn’t take a vacation while you think it over

In rheumatoid arthritis, the inflamed lining of the joint is more than a source of pain. It is active tissue that gradually eats into cartilage and bone. Many people develop erosions on imaging within the first two years of the disease, and some within the first months. An erosion is not a bruise. It will not “clear up by summer.” Treatment can stop it from growing, but pharmacies don’t dispense new cartilage, not even with a prescription.

That is why rheumatologists talk about a “window of opportunity”: early on, the disease is easiest to bring under control while the joints are still intact. A window is not a door; it does not stay open forever. And no one will hang a sign on it saying “Closing in two weeks.”

More on how RA develops and how it is treated is in the rheumatoid arthritis section.

Other diseases are sneakier still. Kidneys affected by lupus don’t hurt. At all. A person feels reasonably well while protein is already showing up in the urine. If kidneys could complain the way knees do, many decisions would be easier. But kidneys are introverts. So in lupus nephritis, decisions rest on lab tests and, when needed, a biopsy, not on how you feel.

And in giant cell arteritis, the clock runs in days: eyesight is at stake. Here “let’s wait” isn’t caution. It is waiting for the very thing we are trying to prevent.

“Let’s try something milder”

This is probably the most popular request in my office. It sounds sensible: start small, save the strong stuff for later. The trouble is that “milder” is not a treatment goal. It is a description of a medicine. The goal is remission or low disease activity. If the mild option doesn’t get you there, we are not protecting your health. We are paying for caution with your joints.

Picture this: the house is on fire, and you ask the firefighters, “Could we start with a glass of water? A hose seems a bit radical.” Out of respect for your feelings, the firefighters start with the glass. The house will not appreciate the respect.

A woman offers a tiny glass of water to a firefighter beside a model house with small, stylized flames.
“Something milder” still has to do the job.

That is exactly the subject of “Afraid of the medication. What about the disease?” Its main point: a medicine comes with a leaflet full of frightening words. The disease comes with no leaflet at all. That doesn’t mean it has nothing to write in one.

What “aggressive” treatment really means

The word is frightening. It sounds as if your doctor plans to carpet-bomb your immune system with the whole arsenal at once. No.

Aggressive does not mean “the maximum of everything, just in case.” It means three things:

  1. Early. Treatment starts once the diagnosis is established, not once the X-ray has something worth showing to medical students.
  2. With a target. We agree in advance what we are aiming for: remission, or at least low disease activity.
  3. With check-ins. Every few months we compare where we are with where we meant to be. In rheumatoid arthritis, for example, if there is no meaningful improvement by three months, or the target hasn’t been reached by six, the plan changes. Not “let’s give it another six months.” It changes.

Doctors call this “treat to target.” In everyday terms, it’s a GPS. It won’t scold you for a wrong turn, but it won’t pretend you’ve arrived, either.

A doctor and a patient look at a navigation tablet beside a winding path leading toward a destination flag.
A shared destination, regular check-ins, and a route that can change.

Sometimes this requires modern biologic or targeted medicines — not as the heavy artillery of last resort, but when they are genuinely indicated. How their benefits and risks are weighed is covered in the guide “Advanced therapy: benefits, risks and the individual.”

Giving up too early is also “a little bit”

There is a mirror-image story. A patient starts methotrexate, three weeks go by, the joints still ache. “It’s not working! Let’s try something else!” Sometimes it’s even shorter: “I took it for three days, it didn’t help, so I stopped.” Three days is less time than some parcels take to arrive, never mind a slow-acting medicine.

DMARDs — disease-modifying antirheumatic drugs — are tortoises. They work deep down, on the machinery of inflammation itself, and that is why they are slow: weeks, sometimes months. Stopping a medicine at week four is like taking a pie out of the oven after five minutes and declaring the recipe a failure. Why this happens and how to get through the “doubtful weeks” is explained in “Why Isn’t My New Medicine Working Yet?”

So an early, active approach is not impatience. It is patience with an alarm clock: we wait as long as the medicine needs, but not a day longer.

A determined tortoise carries a brass alarm clock on its shell as it walks toward a small flag.
Patience, with an alarm clock.

And once I feel good, can I stop?

Another version of “a little bit”: I treated it a little, I feel fine, that’s enough. Alas. Feeling well on treatment usually means the treatment is working, not that it is no longer needed. It is like switching off the air conditioning in July because the room has cooled down — and being genuinely surprised by the heat an hour later. A flare after stopping on your own often arrives two or three months later, late enough that no one connects it to the pills that were “no longer needed.”

Remission is a success, not a finish line. What it does and doesn’t mean is covered in “I’m in remission. Does that mean the disease is gone?” Treatment can sometimes be reduced in sustained remission — together with your doctor and according to a plan, not according to your mood or your neighbor’s advice.

A fair caveat: “monitoring” and “wait and see” are not synonyms

Now for the limits of my favorite joke. Pregnancy is confirmed with a test. A rheumatologic diagnosis is not always clear right away. A positive ANA is not yet lupus; achy joints are not yet arthritis. There are situations where watching is wiser than treating, and I will be the first to tell a patient so. That is what “Early autoimmunity: before a clear diagnosis” and “Positive ANA: understand the result” are about.

But real monitoring has telltale signs:

  • it is clear what we are watching: symptoms, blood tests, imaging;
  • there is a date for the next check;
  • it is agreed in advance what would change the decision.

If none of that is in place, it isn’t monitoring. It’s “wait and see.” A weather forecaster could work the same way, by glancing out the window. And in rheumatology, “wait and see” too often ends with “well, now we’ve seen.”

In other words: while the result is doubtful, the test is repeated. Once it is positive, nobody pretends the line is too faint to count.

About fear

Behind almost every “let’s do just a little” there is fear. Of side effects. Of the word “chemotherapy.” Of the neighbor who “got everything” from those shots. Of the online forum where everyone has died yet somehow keeps posting. Of Dr. Google, who always has time to chat but never has your test results. These are normal fears, and they deserve discussion — in detail, with numbers, and without condescension.

But fear makes a poor attending physician. It always advises waiting and never takes responsibility for the consequences. Everyone understands the dream of a medicine that works from day one, has no side effects and needs no blood tests — we have a whole satirical essay about it, “The Treatment That Doesn’t Exist.” Spoiler: no one has invented it yet.

A good conversation starts with one specific sentence: “What I’m most afraid of is…” From there, you can discuss how real that risk is for you and what can be done to reduce it. The “My treatment plan” worksheet helps with that conversation, and “Your Rheumatology Visit” helps you prepare for the appointment.

And it is better to arrive not with the question “Can I skip treatment?” but with “What are we risking while I wait?”

In short

  • Active inflammation is never “a little bit.” Either it’s under control or it’s at work.
  • Early treatment is a chance to protect what is not yet damaged. Treatment cannot give back what is.
  • “Aggressive” means early, with a target and with check-ins — not “everything at once.”
  • Slow medicines need time. But time with an alarm clock.
  • While the diagnosis is unclear: monitoring with a plan. Once it is clear: treatment with no discount for “wait and see.”

You can’t be a little bit pregnant. You can’t treat active arthritis a little bit. But you can treat it in time — and that may be the best news in this whole article.

Education, not a prescription. Do not start, stop or change treatment on the basis of this article alone — discuss the decision with your treating physician.

© 2026 Olga Goodman, MD · RheumaView

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: How treatment worksinflammationMedication safetyPatient educationTreatmentTreatment decisions